FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2177091330> ?p ?o ?g. }

• W2177091330 endingPage "35050" @default.
• W2177091330 startingPage "35040" @default.
• W2177091330 abstract "This study was designed to investigate whether proton pump inhibitors (PPI, V-ATPase blocker) could increase the effect of cytotoxic agents in chemoresistant epithelial ovarian cancer (EOC). Expression of V-ATPase protein was evaluated in patients with EOC using immunohistochemistry, and patient survival was compared based on expression of V-ATPase mRNA from a TCGA data set. In vitro, EOC cell lines were treated with chemotherapeutic agents with or without V-ATPase siRNA or PPI (omeprazole) pretreatment. Cell survival and apoptosis was assessed using MTT assay and ELISA, respectively. In vivo experiments were performed to confirm the synergistic effect with omeprazole and paclitaxel on tumor growth in orthotopic and patient-derived xenograft (PDX) mouse models. Expression of V-ATPase protein in ovarian cancer tissues was observed in 44 patients (44/59, 74.6%). Higher expression of V-ATPase mRNA was associated with poorer overall survival in TCGA data. Inhibition of V-ATPase by siRNA or omeprazole significantly increased cytotoxicity or apoptosis to paclitaxel in chemoresistant (HeyA8-MDR, SKOV3-TR) and clear cell carcinoma cells (ES-2, RMG-1), but not in chemosensitive cells (HeyA8, SKOV3ip1). Moreover, the combination of omeprazole and paclitaxel significantly decreased the total tumor weight compared with paclitaxel alone in a chemoresistant EOC animal model and a PDX model of clear cell carcinoma. However, this finding was not observed in chemosensitive EOC animal models. These results show that omeprazole pretreatment can increase the effect of chemotherapeutic agents in chemoresistant EOC and clear cell carcinoma via reduction of the acidic tumor microenvironment." @default.
• W2177091330 created "2016-06-24" @default.
• W2177091330 creator A5019886336 @default.
• W2177091330 creator A5026719950 @default.
• W2177091330 creator A5030615595 @default.
• W2177091330 creator A5035817927 @default.
• W2177091330 creator A5038526789 @default.
• W2177091330 creator A5047615329 @default.
• W2177091330 creator A5050287020 @default.
• W2177091330 creator A5057234589 @default.
• W2177091330 creator A5061006522 @default.
• W2177091330 creator A5066554642 @default.
• W2177091330 creator A5072865889 @default.
• W2177091330 creator A5077795933 @default.
• W2177091330 creator A5078485334 @default.
• W2177091330 creator A5081944917 @default.
• W2177091330 creator A5082469456 @default.
• W2177091330 creator A5085553146 @default.
• W2177091330 date "2015-09-19" @default.
• W2177091330 modified "2023-09-25" @default.
• W2177091330 title "Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma" @default.
• W2177091330 cites W1587296274 @default.
• W2177091330 cites W1948560807 @default.
• W2177091330 cites W1965252679 @default.
• W2177091330 cites W1970122162 @default.
• W2177091330 cites W1973835145 @default.
• W2177091330 cites W1979538859 @default.
• W2177091330 cites W1992126390 @default.
• W2177091330 cites W2007193116 @default.
• W2177091330 cites W2011169617 @default.
• W2177091330 cites W2023810324 @default.
• W2177091330 cites W2031092480 @default.
• W2177091330 cites W2037041015 @default.
• W2177091330 cites W2038426489 @default.
• W2177091330 cites W2040000631 @default.
• W2177091330 cites W2040935952 @default.
• W2177091330 cites W2045065956 @default.
• W2177091330 cites W2046585193 @default.
• W2177091330 cites W2062562477 @default.
• W2177091330 cites W2064840876 @default.
• W2177091330 cites W2068325902 @default.
• W2177091330 cites W2096412326 @default.
• W2177091330 cites W2101431866 @default.
• W2177091330 cites W2102577783 @default.
• W2177091330 cites W2104824311 @default.
• W2177091330 cites W2106951984 @default.
• W2177091330 cites W2119103023 @default.
• W2177091330 cites W2121741947 @default.
• W2177091330 cites W2123696077 @default.
• W2177091330 cites W2128414062 @default.
• W2177091330 cites W2140996395 @default.
• W2177091330 cites W2143433681 @default.
• W2177091330 cites W2151356556 @default.
• W2177091330 cites W2158734599 @default.
• W2177091330 cites W2160251189 @default.
• W2177091330 cites W2165836181 @default.
• W2177091330 cites W2168148385 @default.
• W2177091330 cites W2279798924 @default.
• W2177091330 doi "https://doi.org/10.18632/oncotarget.5319" @default.
• W2177091330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4741507" @default.
• W2177091330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26418900" @default.
• W2177091330 hasPublicationYear "2015" @default.
• W2177091330 type Work @default.
• W2177091330 sameAs 2177091330 @default.
• W2177091330 citedByCount "43" @default.
• W2177091330 countsByYear W21770913302016 @default.
• W2177091330 countsByYear W21770913302017 @default.
• W2177091330 countsByYear W21770913302018 @default.
• W2177091330 countsByYear W21770913302019 @default.
• W2177091330 countsByYear W21770913302020 @default.
• W2177091330 countsByYear W21770913302021 @default.
• W2177091330 countsByYear W21770913302022 @default.
• W2177091330 countsByYear W21770913302023 @default.
• W2177091330 crossrefType "journal-article" @default.
• W2177091330 hasAuthorship W2177091330A5019886336 @default.
• W2177091330 hasAuthorship W2177091330A5026719950 @default.
• W2177091330 hasAuthorship W2177091330A5030615595 @default.
• W2177091330 hasAuthorship W2177091330A5035817927 @default.
• W2177091330 hasAuthorship W2177091330A5038526789 @default.
• W2177091330 hasAuthorship W2177091330A5047615329 @default.
• W2177091330 hasAuthorship W2177091330A5050287020 @default.
• W2177091330 hasAuthorship W2177091330A5057234589 @default.
• W2177091330 hasAuthorship W2177091330A5061006522 @default.
• W2177091330 hasAuthorship W2177091330A5066554642 @default.
• W2177091330 hasAuthorship W2177091330A5072865889 @default.
• W2177091330 hasAuthorship W2177091330A5077795933 @default.
• W2177091330 hasAuthorship W2177091330A5078485334 @default.
• W2177091330 hasAuthorship W2177091330A5081944917 @default.
• W2177091330 hasAuthorship W2177091330A5082469456 @default.
• W2177091330 hasAuthorship W2177091330A5085553146 @default.
• W2177091330 hasBestOaLocation W21770913301 @default.
• W2177091330 hasConcept C109316439 @default.
• W2177091330 hasConcept C121608353 @default.
• W2177091330 hasConcept C126322002 @default.
• W2177091330 hasConcept C150903083 @default.
• W2177091330 hasConcept C154317977 @default.
• W2177091330 hasConcept C185592680 @default.
• W2177091330 hasConcept C190283241 @default.

• next